Vektor Medical has filed a notice of an exempt offering of securities to raise $37,498,887.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Vektor Medical is raising up to $37,498,887.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Robert Krummen played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Vektor Medical
Vektor Medical is on a mission to revolutionize arrhythmia care. The FDA-cleared vMap technology, is an AI-based arrhythmia analysis tool, created to improve cardiac ablation outcomes, optimize workflows and increase procedural efficiency. We are advancing care for arrhythmia patients by unlocking insights contained in a standard ECG. vMap is an AI-based arrhythmia analysis tool, created to improve cardiac ablation outcomes, optimize workflows and increase procedural efficiency. Cardiac arrhythmias cause 10% of global deaths and over 25% of adults over 40 will develop a serious arrhythmia. Untreated arrhythmias not only raise the risk of death but are also associated with serious co-morbidities such as stroke and dementia.
To learn more about Vektor Medical, visit http://www.vektormedical.com/
Contact:
Robert Krummen, Chief Executive Officer
858-405-0094
https://www.linkedin.com/in/robertkrummen/
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.